Innovation Pharmaceuticals Inc (IPIX)

[Whoops]

My take on why "she" discontinued comes from Leo's statement in the PR...

"That’s an everyday practice in oncology, especially when a drug regimen, such as the strict protocol with the Kevetrin trial where dosing levels and intervals absolutely cannot be changed. - See more at: http://cellceutix.com/cellceutix-reports-spleen-lesion-disappears-in-patient-with-metastatic-stage-4-ovarian-cancer-in-clinical-trial-of-anti-cancer-drug-kevetrin/#sthash.L9R5xAAo.dpuf";

It sounds like she wanted to accelerate her Kevetrin dosing cycle to me. She was in the trials for 3 cycles, perhaps starting at the 150 dose that is more than 3 months. She probably got frustrated as many of us do with Dana Farbers pace etc. If Kevetrin can clinically stabilize a stage 4 ovarian cancer patient i.e. prolonged her life for 3 months that should be FDA orphan/fast track designation alone not even considering spleen lesion disappearing. She is still a stage 4 cancer patient perhaps Kevetrin stabilized her enough to go back to quicker traditional therapy.

When my father was at stage 4 liver cancer it would have been a miracle if he could have gone in for 3 treatments of a an experimental drug and then be able to go for a walk with me. I would have liked that very much. I think some people under estimate how sick stage 4 is..to me the patient is bedridden. Also remember this is primarily a dose escalation safety study it is not optimized for treatment. Due to the quick clearance, last I heard, the company would move to twice a week dose.

Harvard's Dana Farber allowed the Cellceutix to share this information..that in of itself is very significant.